Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia
Microbiology Spectrum · 04.08.2026 · 14 (8)
DOI: 10.1128/spectrum.00442-26 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Microbiology Spectrum, erschienen am 04.08.2026. Verfasst von Victoria Sanderford und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Salvage Therapy, Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Bacteremia. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Our retrospective observational cohort study investigated the effect of the timing of escalation to dual salvage therapy utilizing ceftaroline with vancomycin or daptomycin for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia on patient outcomes. Eligibility criteria included age ≥18 years old, at least one positive blood culture for methicillin-resistant Staphylococcus aureus , and receipt of salvage therapy consisting of ceftaroline in combination with either vancomycin or daptomycin for any duration during their bloodstream infection within our health system over a 10-year period. This resulted in the inclusion of 189 adult patients. Patients were stratified by the timing of ceftaroline initiation: ≤5 days (early initiation) versus >5 days (late initiation) from index positive culture. The study populations were similar, although there was a higher prevalence of persons who inject drugs started on early salvage therapy (36.0% versus 18.0%, P = 0.005) and fewer patients with type II diabetes (25.8% versus 41.0%, P = 0.028). Analysis revealed no statistically significant differences between 90-day all-cause mortality or readmission rates in either group; however, there was less 90-day microbiologic recurrence in the early initiation group (3.4% versus 11.0%, P = 0.046). Patients started on early salvage therapy also had fewer total days of bacteremia (7.0 versus 10.5 days, P < 0.001), fewer metastatic foci of infection (61.8% versus 82.0%, P = 0.002), and a shorter duration of treatment (46.0 versus 50.0 days, P = 0.013). IMPORTANCE Treatment of methicillin-resistant Staphylococcus aureus bacteremia remains a challenge due to its high morbidity and mortality. Ceftaroline has been studied for off-label utilization in dual salvage therapy with daptomycin or vancomycin in these patients, although current data regarding the optimal timing for its addition are limited. We sought to address this knowledge gap with our retrospective review of patient outcomes at our hospital system who received ceftaroline for this indication. Overall, earlier initiation of ceftaroline-based dual therapy was beneficial, as evidenced by reduced microbiologic recurrence, shorter duration of bacteremia, reduced metastatic disease, and subsequent shorter duration of therapy if patients were escalated to dual salvage therapy with ceftaroline within 5 days of the index culture.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina Health, Charleston, South Carolina, USA.
- Department of Pharmacy Services, Medical University of South Carolina Health, Charleston, South Carolina, USA.
- Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, USA.
- Department of Pediatrics, Division of Infectious Diseases, Medical University of South Carolina Health, Charleston, South Carolina, USA.
ORCID-Profile: Victoria Sanderford, Richard Lueking
Zitieren
APA
Sanderford, V., Tabliago, N. R. A., Alnami, S., Spencer, S., Colven, R., Rey Alvira-Arill, G., Gruss, Z., Ehrenberger, L., Hamby, A., Kosharek, A., Thacker, S., Mediwala Hornback, K., Morrisette, T., & Lueking, R. (2026). Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia. Microbiology Spectrum, 14(8). https://doi.org/10.1128/spectrum.00442-26
Vancouver
Sanderford V, Tabliago NRA, Alnami S, Spencer S, Colven R, Rey Alvira-Arill G, et al. Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia. Microbiology Spectrum. 2026;14(8). doi:10.1128/spectrum.00442-26
BibTeX
@article{Sanderford2026,
author = {Sanderford, Victoria and Tabliago, Nikko Rowe A and Alnami, Sarah and Spencer, Susan and Colven, Rachel and Rey Alvira-Arill, Gustavo and Gruss, Zachary and Ehrenberger, Laura and Hamby, Aaron and Kosharek, Abby and Thacker, Stephen and Mediwala Hornback, Krutika and Morrisette, Taylor and Lueking, Richard},
title = {Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia},
journal = {Microbiology Spectrum},
year = {2026},
volume = {14},
number = {8},
doi = {10.1128/spectrum.00442-26}
}
EUVIMED